Cargando…
Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review
BACKGROUND: Heart transplant (HTX) recipients are at a significantly higher risk of adverse clinical outcomes, due to chronic immunosuppression and co-existence of other chronic conditions, when contracting the SARS-CoV-2 infection. Although vaccination against SARS-CoV-2 is currently the most promi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174554/ https://www.ncbi.nlm.nih.gov/pubmed/35693423 http://dx.doi.org/10.1177/11795484221105327 |
_version_ | 1784722261731704832 |
---|---|
author | Shoar, Saeed Prada-Ruiz, Adriana C. Carolina Patarroyo-Aponte, Gabriel Chaudhary, Ashok Sadegh Asadi, Mohammad |
author_facet | Shoar, Saeed Prada-Ruiz, Adriana C. Carolina Patarroyo-Aponte, Gabriel Chaudhary, Ashok Sadegh Asadi, Mohammad |
author_sort | Shoar, Saeed |
collection | PubMed |
description | BACKGROUND: Heart transplant (HTX) recipients are at a significantly higher risk of adverse clinical outcomes, due to chronic immunosuppression and co-existence of other chronic conditions, when contracting the SARS-CoV-2 infection. Although vaccination against SARS-CoV-2 is currently the most promising measure for the prevention of severe Coronavirus Disease 2019 (COVID-19) among solid organ transplant recipients, the extent of immune response and its protective efficacy among patients receiving HTX has not been sufficiently studied. METHODS: We performed a systematic review of the literature by inquiring PubMed/Medline to identify original studies among HTX recipients, who had received at least one dose of the SARS-CoV-2 vaccine. Data on the measured humoral or cellular immune response was collected from all the eligible studies. Factors associated with a poor immune response were further investigated within these studies. RESULTS: A total of 12 studies comprising 563 HTX recipients were included. The average age of the study participants was 60.8 years. Sixty four percent of the study population were male. Ninety percent of the patients had received an mRNA vaccine (Pfizer/ BNT162b2 or Moderna/mRNA-1273). A positive immune response to SARS-CoV-2 vaccine was variably reported in 0% to 100% of the patients. Older age (> 65 years), vaccine dose (first, second, or third), time since HTX to the first dose of the vaccine, the time interval between the latest dose of the vaccine and measurement of the immune response, and the type of immunosuppressive regimen were all indicated as potential determinants of a robust immune response to the SARS-CoV-2 vaccination. CONCLUSION: HTX recipients demonstrate a weaker immune response to the vaccination against SARS-CoV-2 compared to the general population. Older age, anti-metabolite agents such as mycophenolate mofetil, and vaccination during the first year following the HTX have been indicated as potential determinants of a poor immune response. |
format | Online Article Text |
id | pubmed-9174554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-91745542022-06-09 Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review Shoar, Saeed Prada-Ruiz, Adriana C. Carolina Patarroyo-Aponte, Gabriel Chaudhary, Ashok Sadegh Asadi, Mohammad Clin Med Insights Circ Respir Pulm Med Systematic Review BACKGROUND: Heart transplant (HTX) recipients are at a significantly higher risk of adverse clinical outcomes, due to chronic immunosuppression and co-existence of other chronic conditions, when contracting the SARS-CoV-2 infection. Although vaccination against SARS-CoV-2 is currently the most promising measure for the prevention of severe Coronavirus Disease 2019 (COVID-19) among solid organ transplant recipients, the extent of immune response and its protective efficacy among patients receiving HTX has not been sufficiently studied. METHODS: We performed a systematic review of the literature by inquiring PubMed/Medline to identify original studies among HTX recipients, who had received at least one dose of the SARS-CoV-2 vaccine. Data on the measured humoral or cellular immune response was collected from all the eligible studies. Factors associated with a poor immune response were further investigated within these studies. RESULTS: A total of 12 studies comprising 563 HTX recipients were included. The average age of the study participants was 60.8 years. Sixty four percent of the study population were male. Ninety percent of the patients had received an mRNA vaccine (Pfizer/ BNT162b2 or Moderna/mRNA-1273). A positive immune response to SARS-CoV-2 vaccine was variably reported in 0% to 100% of the patients. Older age (> 65 years), vaccine dose (first, second, or third), time since HTX to the first dose of the vaccine, the time interval between the latest dose of the vaccine and measurement of the immune response, and the type of immunosuppressive regimen were all indicated as potential determinants of a robust immune response to the SARS-CoV-2 vaccination. CONCLUSION: HTX recipients demonstrate a weaker immune response to the vaccination against SARS-CoV-2 compared to the general population. Older age, anti-metabolite agents such as mycophenolate mofetil, and vaccination during the first year following the HTX have been indicated as potential determinants of a poor immune response. SAGE Publications 2022-06-05 /pmc/articles/PMC9174554/ /pubmed/35693423 http://dx.doi.org/10.1177/11795484221105327 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Systematic Review Shoar, Saeed Prada-Ruiz, Adriana C. Carolina Patarroyo-Aponte, Gabriel Chaudhary, Ashok Sadegh Asadi, Mohammad Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review |
title | Immune Response to SARS-CoV-2 Vaccine among Heart Transplant
Recipients: A Systematic Review |
title_full | Immune Response to SARS-CoV-2 Vaccine among Heart Transplant
Recipients: A Systematic Review |
title_fullStr | Immune Response to SARS-CoV-2 Vaccine among Heart Transplant
Recipients: A Systematic Review |
title_full_unstemmed | Immune Response to SARS-CoV-2 Vaccine among Heart Transplant
Recipients: A Systematic Review |
title_short | Immune Response to SARS-CoV-2 Vaccine among Heart Transplant
Recipients: A Systematic Review |
title_sort | immune response to sars-cov-2 vaccine among heart transplant
recipients: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174554/ https://www.ncbi.nlm.nih.gov/pubmed/35693423 http://dx.doi.org/10.1177/11795484221105327 |
work_keys_str_mv | AT shoarsaeed immuneresponsetosarscov2vaccineamonghearttransplantrecipientsasystematicreview AT pradaruizadrianaccarolina immuneresponsetosarscov2vaccineamonghearttransplantrecipientsasystematicreview AT patarroyoapontegabriel immuneresponsetosarscov2vaccineamonghearttransplantrecipientsasystematicreview AT chaudharyashok immuneresponsetosarscov2vaccineamonghearttransplantrecipientsasystematicreview AT sadeghasadimohammad immuneresponsetosarscov2vaccineamonghearttransplantrecipientsasystematicreview |